Skip to content

C. T. J. Lamers

3 papers in the library · 267 citations · publishing 2003-2006

Papers

Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls

Journal of Psychopharmacology March 1, 2006 C. T. J. Lamers, A. Bechara, M. Rizzo et al. 113 citations

People who use both MDMA (ecstasy) and marijuana (THC) report more depression and anxiety than those who use only THC or no drugs. Memory is impaired in both drug-using groups. MDMA/THC users have slower psychomotor speed and less mental flexibility than non-users. THC users show less mental flexibility and worse decision-making than non-users, but these deficits are similar to those in MDMA/THC users. The findings suggest that some cognitive impairments previously attributed to MDMA may actually be due to concurrent THC use, while MDMA use is specifically linked to increased depression and anxiety.

Dissociable Effects of a Single Dose of Ecstasy (MDMA) on Psychomotor Skills and Attentional Performance

Journal of Psychopharmacology December 1, 2003 C. T. J. Lamers, Johannes G. Ramaekers, N. D. Muntjewerff et al. 105 citations

A single 75 mg dose of MDMA improved psychomotor performance, including movement speed and tracking in both single and divided attention tasks, but impaired the ability to predict object movement under divided attention, which may indicate impairment of driving-relevant skills. No effect was found on visual search, planning, or semantic memory retrieval. Alcohol 0.5 g/kg was also tested but its effects are not described here. The findings suggest MDMA can both enhance and impair specific cognitive and motor functions relevant to driving.

Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic–Mass Spectrometric Assay for Enantioselective Measurement of the Designer Drugs MDEA, MDMA, and MDA and Its Application to Samples from a Controlled Study with MDMA

Clinical Chemistry August 11, 2005 Frank T. Peters, Nele Samyn, C. T. J. Lamers et al. 49 citations

An assay was developed to measure the enantiomers of the designer drugs MDA, MDMA, and MDEA in small plasma volumes (0.2 mL or less). After extraction and derivatization, the enantiomers were separated by gas chromatography and detected by mass spectrometry within 17 minutes. The method was linear for MDA at 1–50 μg/L and for MDMA and MDEA at 5–250 μg/L per enantiomer, with extraction yields of 82.1%–95.3%. Applied to samples from a controlled study after a single 75 mg dose of racemic MDMA, the assay showed that R-(−)-MDMA concentrations significantly exceeded those of S-(+)-MDMA, with ratios always above 1.0 and increasing over time. S-(+)-MDA concentrations exceeded those of R-(−)-MDA, with ratios also increasing but remaining below 1.0.